Compare Boston Scientific Corporation (BSX) vs Nucor Corporation (NUE) Price & Performance

Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.

BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.

Nucor (NUE) trades at $233.00, up 2.48% over the past day, supported by a bullish technical signal and strong earnings beats in recent quarters. The stock benefits from a solid balance sheet with a debt-to-asset ratio of 20.23% (2025 company filing) and a 53-year dividend growth streak. Revenue for 2025 was $32.49 billion, with net income of $1.74 billion, though margins have compressed from peak levels. Recent news highlights a joint venture to address power infrastructure bottlenecks and positive analyst sentiment.

Outlook remains positive with a consensus price target of $262.89 (analyst reports July 2026), implying ~13% upside. Key opportunities include steel price strength and strategic expansions, but risks involve cyclical demand weakness and margin pressure. Institutional ownership trends and buy ratings (62.5% of analysts) support a constructive view, though investors should monitor Q2 2026 earnings for confirmation of guidance.